• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Mainz Biomed N.V.

    3/1/23 6:38:43 AM ET
    $MYNZ
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MYNZ alert in real time by email
    SC 13G 1 tm238083d1_sc13g.htm SC 13G

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    (Amendment No. )*

     

    Under the Securities Exchange Act of 1934

     

    MAINZ BIOMED N.V.
    (Name of Issuer)
     
    Ordinary Shares, nominal value of €0.01 per share
    (Titles of Class of Securities)
     
    N5436L101
    (CUSIP Number)
     
    December 31, 2022
    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨ Rule 13d-1(b)
    ¨ Rule 13d-1(c)
    x Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended (the “Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. N5436L101 SCHEDULE 13G Page 2 of 6

     

    1

    NAME OF REPORTING PERSON OR

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

    KfW

     
    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY  
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Germany

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED

    BY EACH

    REPORTING

    PERSON

    WITH

    5

    SOLE VOTING POWER

    1,237,501

    6

    SHARED VOTING POWER

    0

    7

    SOLE DISPOSITIVE POWER

    1,237,501

    8

    SHARED DISPOSITIVE POWER

    0

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    1,237,501

     
    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    8.5% (1)

     
    12

    TYPE OF REPORTING PERSON

    OO

     

     

    (1) Calculated based on 14,492,973 ordinary shares of Mainz Biomed N.V. outstanding as of December 27, 2022, as disclosed in its prospectus filed with the Securities and Exchange Commission on January 10, 2023.

     

     

     

     

    CUSIP No. N5436L101 SCHEDULE 13G Page 3 of 6

     

    Item 1(a). Name of Issuer:
       
      Mainz Biomed N.V.
       
    Item 1(b). Address of Issuer’s Principal Executive Offices:
       
      Robert Koch Strasse 50, 55129 Mainz, Germany
       
    Item 2(a). Name of Person Filing:
       
      Kreditanstalt für Wiederaufbau
       
    Item 2(b). Address of Principal Business Office or, if none, Residence:
       
      Palmengartenstrasse 5-9, 60325 Frankfurt am Main, Germany
       
    Item 2(c). Citizenship:
       
      Germany
       
    Item 2(d). Titles of Classes of Securities:
       
      Ordinary Shares, nominal value of €0.01 per share
       
    Item 2(e). CUSIP Number:
       
      N5436L101

     

    Item 3.

    If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c),

    Check Whether the Person Filing is a(n):

       

      (a) ¨ Broker or dealer registered under Section 15 of the Exchange Act (15 U.S.C. 78o).
      (b) ¨ Bank as defined in Section 3(a)(6) of the Exchange Act (15 U.S.C. 78c).

     

     

     

     

    CUSIP No. N5436L101 SCHEDULE 13G Page 4 of 6

     

      (c) ☐ Insurance company as defined in Section 3(a)(19) of the Exchange Act (15 U.S.C. 78c).
           
      (d) ☐ Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
           
      (e) ☐ Investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).
           
      (f) ☐ Employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F).
           
      (g) ☐ Parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G).
           
      (h) ☐ Savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813).
           
      (i) ☐ Church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3).
           
      (j) ☐ Non-U.S. institution, in accordance with § 240.13d-1(b)(1)(ii)(J).
           
      (k) ☐ Group in accordance with §240.13d-1(b)(1)(ii)(K).
           
      If filing as a non-U.S. institution in accordance with §240. 13d-1(b)(1)(ii)(J), please specify the type of institution: __________

     

    Item 4. Ownership

     

      (a) Amount beneficially owned:
         
        See response to Item 9 on the cover page.
         
      (b) Percent of class:
         
        See response to Item 11 on the cover page.
         
      (c) Number of shares as to which such person has:
         

        (i) Sole power to vote or to direct the vote:
           
          See response to Item 5 on the cover page.
           
        (ii) Shared power to vote or to direct the vote:
           
          See response to Item 6 on the cover page.

     

     

     

     

    CUSIP No. N5436L101 SCHEDULE 13G Page 5 of 6

     

        (iii) Sole power to dispose or to direct the disposition of:
           
          See response to Item 7 on the cover page.
           
        (iv) Shared power to dispose or to direct the disposition of:
           
          See response to Item 8 on the cover page.

     

    Item 5. Ownership of Five Percent or Less of a Class.
       
      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ¨.
       
    Item 6. Ownership of More than Five Percent on Behalf of Another Person.
       
      Not Applicable.
       
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.
       
      Not Applicable.
       
    Item 8. Identification and Classification of Members of the Group.
       
      Not Applicable.
       
    Item 9. Notice of Dissolution of Group.
       
      Not Applicable.
       
    Item 10. Certification.
       
      Not Applicable.

     

     

     

     

    CUSIP No. N5436L101 SCHEDULE 13G Page 6 of 6

     

    SIGNATURE

     

    After reasonable inquiry and to the best of our knowledge and belief, the undersigned hereby certify on behalf of KfW that the information set forth in this statement is true, complete and correct.

     

    Dated: March 1, 2023

     

      KfW
         
      By: /s/ Christian Berlin
      Name: Christian Berlin
      Title: First Vice President
         
      By: /s/ Uwe Dittrich
      Name: Uwe Dittrich
      Title: Vice President

     

     

     

    Get the next $MYNZ alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MYNZ

    DatePrice TargetRatingAnalyst
    2/14/2025$14.00Buy
    Maxim Group
    11/25/2024Buy → Neutral
    H.C. Wainwright
    11/21/2023Overweight → Neutral
    Cantor Fitzgerald
    6/21/2022$25.00Buy
    H.C. Wainwright
    More analyst ratings

    $MYNZ
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Mainz Biomed Announces Pricing of $4.0 Million Follow-On Offering of Ordinary Shares and Warrants

      BERKELEY, Calif. and MAINZ, Germany, May 19, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), a molecular genetics diagnostic company specializing in the early detection of cancer, today announced the pricing of a follow-on offering of 2,000,000 units, with each unit consisting of one ordinary share (or pre-funded warrant in lieu thereof), one Series A warrant to purchase one ordinary share, and one Series B warrant to purchase one ordinary share for gross proceeds of approximately $4.0 million. Each unit is being sold at an effective offering price of $2.00 per unit. Each Series A warrant will be immediately exercisable at an exercise price of $2

      5/19/25 8:01:15 PM ET
      $MYNZ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mainz Biomed Announces Interim Read Out For Its eAArly DETECT 2 Clinical Study

      Company intends to provide an interim read out by the end of summer 2025 Top-line results anticipated in Q4 2025; study on track to support U.S. pivotal trial initiation in 2026 BERKELEY, Calif. and MAINZ, Germany, May 16, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today that it intends to provide an interim read out of its eAArly DETECT 2 feasibility study by the end of summer 2025. The study is evaluating the Company's next-generation colorectal cancer (CRC) screening test that integrates Mainz Biomeds proprietary mRNA biomarkers, an AI-devel

      5/16/25 8:01:00 AM ET
      $MYNZ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mainz Biomed Enters into Technology Partnership with EDX Medical Group

      BERKELEY, Calif. and MAINZ, Germany, April 29, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), a molecular genetics diagnostic company specializing in the early detection of cancer, has entered into a technology partnership with UK-based EDX Medical Group plc (AQSE: EDX), which develops innovative digital diagnostic products and services supporting personalized treatments for cancer, cardiovascular and infectious diseases. Under the agreement, EDX Medical will access Mainz Biomed's molecular diagnostic technology as part of the expansion of its portfolio of products for sale in the UK. "We are delighted to join forces with EDX Medical Limited t

      4/29/25 8:01:00 AM ET
      $MYNZ
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MYNZ
    Financials

    Live finance-specific insights

    See more
    • Mainz Biomed Acquires Entire Intellectual Property Portfolio for its Colorectal Cancer Diagnostic Test Program

      Transaction entails executing option agreements to purchase IP portfolio associated with current ColoAlert product and the novel gene expression (mRNA) biomarkers being evaluated in ColoFuture/eAARLY DETECT Studies BERKELEY, Calif. and MAINZ, Germany, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today the execution of its option from Uni Targeting Research AS to acquire all of the previously licensed scientific intellectual property ("IP") for its flagship product ColoAlert, a highly efficacious, and easy-to-use detection test for colorec

      2/21/23 3:01:00 AM ET
      $MYNZ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mainz Biomed Acquires Exclusive Rights to Novel mRNA Biomarkers

      Potential for ColoAlert to Emerge as the Most Robust and Accurate At-home Screening Test for Colorectal Cancer Biomarkers Demonstrated Unique Ability to Identify Curable Precancerous Colonic Polyps as well as Curable Early-Stage Colorectal Cancer BERKELEY, Calif. and MAINZ, Germany, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today it has entered into a Technology Rights Agreement with Socpra Sciences Santé Et Humaines S.E.C. ("TTS") to access a portfolio of novel mRNA biomarkers for potential future integration into ColoAlert,

      1/5/22 3:01:00 AM ET
      $MYNZ
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MYNZ
    SEC Filings

    See more
    • SEC Form EFFECT filed by Mainz Biomed N.V.

      EFFECT - MAINZ BIOMED N.V. (0001874252) (Filer)

      5/19/25 12:15:25 AM ET
      $MYNZ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Mainz Biomed N.V.

      SCHEDULE 13G/A - MAINZ BIOMED N.V. (0001874252) (Subject)

      5/15/25 3:44:59 PM ET
      $MYNZ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form F-1/A filed by Mainz Biomed N.V.

      F-1/A - MAINZ BIOMED N.V. (0001874252) (Filer)

      5/14/25 4:20:36 PM ET
      $MYNZ
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MYNZ
    Leadership Updates

    Live Leadership Updates

    See more
    • Mainz Biomed Enters into Technology Partnership with EDX Medical Group

      BERKELEY, Calif. and MAINZ, Germany, April 29, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), a molecular genetics diagnostic company specializing in the early detection of cancer, has entered into a technology partnership with UK-based EDX Medical Group plc (AQSE: EDX), which develops innovative digital diagnostic products and services supporting personalized treatments for cancer, cardiovascular and infectious diseases. Under the agreement, EDX Medical will access Mainz Biomed's molecular diagnostic technology as part of the expansion of its portfolio of products for sale in the UK. "We are delighted to join forces with EDX Medical Limited t

      4/29/25 8:01:00 AM ET
      $MYNZ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mainz Biomed Announces Petra Smeltzer Starke to Join Company as Brand Ambassador

      BERKELEY, Calif. and MAINZ, Germany, Sept. 18, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today the addition of Petra Smeltzer Starke as a Brand Ambassador for the Company. As Brand Ambassador she will help the Company in the development and dissemination of messaging focused on the importance of early detection of colorectal cancer. "We are excited about Petra joining our team as Brand Ambassador. Her broad and deep experience will be invaluable to us as we bring our next generation colorectal cancer screening product to market, with the

      9/18/24 8:01:00 AM ET
      $MYNZ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mainz Biomed Appoints Tarrin Khairi-Taraki as VP of Commercial Operations

      Former Natera Manager will oversee all aspects of sales and support in EMEA, ensuring the continued commercialization of ColoAlert® across the region BERKELEY, Calif. and MAINZ, Germany, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), a molecular genetics diagnostic company specializing in the early detection of cancer, is proud to announce the appointment of Tarrin Khairi-Taraki as Vice President of Commercial Operations, EMEA. Tarrin will play a pivotal role in steering Mainz Biomed's continued success, focusing on the commercialization of its flagship product, ColoAlert® — a highly effective and user-friendly at-home detection test f

      10/26/23 8:01:00 AM ET
      $MYNZ
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MYNZ
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Maxim Group initiated coverage on Mainz Biomed B.V. with a new price target

      Maxim Group initiated coverage of Mainz Biomed B.V. with a rating of Buy and set a new price target of $14.00

      2/14/25 8:10:14 AM ET
      $MYNZ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mainz Biomed B.V. downgraded by H.C. Wainwright

      H.C. Wainwright downgraded Mainz Biomed B.V. from Buy to Neutral

      11/25/24 7:48:30 AM ET
      $MYNZ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mainz Biomed B.V. downgraded by Cantor Fitzgerald

      Cantor Fitzgerald downgraded Mainz Biomed B.V. from Overweight to Neutral

      11/21/23 7:33:52 AM ET
      $MYNZ
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MYNZ
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Mainz Biomed N.V.

      SC 13G/A - MAINZ BIOMED N.V. (0001874252) (Subject)

      10/7/24 4:47:27 PM ET
      $MYNZ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Mainz Biomed N.V. (Amendment)

      SC 13G/A - MAINZ BIOMED N.V. (0001874252) (Subject)

      2/13/24 2:39:04 PM ET
      $MYNZ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Mainz Biomed N.V.

      SC 13G - MAINZ BIOMED N.V. (0001874252) (Subject)

      3/1/23 6:38:43 AM ET
      $MYNZ
      Biotechnology: Pharmaceutical Preparations
      Health Care